Vimkunya (Chikungunya vaccine (recombinant, adsorbed))
PRIMEAdditional monitoring
- Region
- 🇪🇺 EU
- Active substance
- Chikungunya vaccine (recombinant, adsorbed)
- Company
- Bavarian Nordic A/S
- Status
- Authorised
- Therapeutic area
- Chikungunya virus
- CHMP opinion
- Thu 30 Jan 2025
- EU approval
- Fri 28 Feb 2025
- Designations
- PRIME, Additional monitoring
- Application
- EMEA/H/C/005470
- Official record
- www.ema.europa.eu
Indication
Vimkunya is indicated for active immunisation for the prevention of disease caused by chikungunya virus (CHIKV) in individuals 12 years and older. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Follow Vimkunya
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.